1
|
Petrillo A, Alsina M, Ben-Aharon I. Controversies in upper GI oncology: early-onset gastric cancer. ESMO Open 2024; 9:102925. [PMID: 38663169 PMCID: PMC11061208 DOI: 10.1016/j.esmoop.2024.102925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2024] Open
Affiliation(s)
- A Petrillo
- Medical Oncology Unit, Ospedale del mare, Naples, Italy.
| | - M Alsina
- Department of Medical Oncology, Hospital Universitario de Navarra, Navarrabiomed, Navarra, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - I Ben-Aharon
- Fishman Oncology Center, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel
| |
Collapse
|
2
|
Petrillo A, Derks S, Smyth EC. Controversies in upper GI oncology: MSI-H in gastroesophageal adenocarcinoma. ESMO Open 2024; 9:102229. [PMID: 38244348 PMCID: PMC10835121 DOI: 10.1016/j.esmoop.2023.102229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2024] Open
Affiliation(s)
- A Petrillo
- Medical Oncology Unit, Ospedale del Mare, Naples, Italy.
| | - S Derks
- Amsterdam UMC location Free University, Medical Oncology, Amsterdam; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam; Oncode Institute, Utrecht, The Netherlands
| | - E C Smyth
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK
| |
Collapse
|
3
|
Petrillo A, Maron SB, Sundar R. Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not? ESMO Open 2023; 8:101211. [PMID: 37054477 PMCID: PMC10123152 DOI: 10.1016/j.esmoop.2023.101211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/15/2023] Open
Affiliation(s)
- A Petrillo
- Medical Oncology Unit, Ospedale del mare, Naples, Italy.
| | - S B Maron
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R Sundar
- Department of Haematology-Oncology, National University Cancer Institute, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| |
Collapse
|
4
|
Cardone C, De Stefano A, Rosati G, Cassata A, Silvestro L, Borrelli M, Di Gennaro E, Romano C, Nappi A, Zanaletti N, Foschini F, Casaretti R, Tatangelo F, Lastoria S, Raddi M, Bilancia D, Granata V, Setola S, Petrillo A, Vitagliano C, Gargiulo P, Arenare L, Febbraro A, Martinelli E, Ciardiello F, Delrio P, Budillon A, Piccirillo MC, Avallone A. Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study. ESMO Open 2023; 8:100748. [PMID: 36603521 PMCID: PMC10024144 DOI: 10.1016/j.esmoop.2022.100748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 11/18/2022] [Accepted: 11/23/2022] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Maintaining angiogenesis inhibition and switching the chemotherapy backbone represent the current second-line therapy in patients with RAS-mutant metastatic colorectal cancer (mCRC). Regorafenib, an oral multikinase inhibitor, prolonged overall survival (OS) in the chemorefractory setting. MATERIALS AND METHODS STREAM was an academic, multicenter, single-arm phase II trial, evaluating the activity of regorafenib in RAS-mutant mCRC, in terms of the rate of patients who were progression-free after 6 months from study entry (6mo-PF). Patients were pretreated with fluoropyrimidine, oxaliplatin, and bevacizumab. According to Simon's two-stage design, ≥18 patients 6mo-PF were needed in the overall population (N = 46). Secondary endpoints were safety, objective response rate (ORR), progression-free survival (PFS), and OS. Early metabolic response by [18F]2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography ([18F]-FDG PET/CT) scan was an exploratory endpoint. EudraCT Number: 2015-001105-13. RESULTS The number of patients 6mo-PF was 8/22 at the first stage and 14/46 in the overall population. The ORR was 10.9%, disease control rate was 54.6%, median (m)PFS was 3.6 months [95% confidence interval (CI) 1.9-6.7 months], mOS was 18.9 months (95% CI 10.3-35.3 months), and mPFS2 (from study entry to subsequent-line progression) was 13.3 months (95% CI 8.4-19.7 months). Long benefiter patients (>6mo-PF) significantly more often had a single metastatic site and lung-limited disease. No unexpected toxicity was reported. Grade ≥3 events occurred in 39.1% of patients, with hand-foot syndrome (13%), fatigue, and hyperbilirubinemia (6.5%) occurring mostly. Baseline metabolic assessment was associated with OS in the multivariate analysis, while early metabolic response was not associated with clinical outcomes. CONCLUSIONS The study did not meet its primary endpoint. However, regorafenib was well tolerated and did not preclude subsequent treatments. Patients with good prognostic features (single metastatic site and lung-limited disease) reported clinical benefit with regorafenib. The exploratory metabolic analysis suggests that baseline [18F]-FDG PET/CT might be useful to select patients with a favorable outcome. A chemotherapy-free interval with regorafenib was associated with durable disease control in a selected group of patients with favorable clinical characteristics.
Collapse
Affiliation(s)
- C Cardone
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. https://twitter.com/clacardone
| | - A De Stefano
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. https://twitter.com/alfdestefano
| | - G Rosati
- Medical Oncology Unit, S. Carlo Hospital, Potenza, Italy
| | - A Cassata
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - L Silvestro
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - M Borrelli
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - E Di Gennaro
- Experimental Pharmacology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - C Romano
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - A Nappi
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - N Zanaletti
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - F Foschini
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - R Casaretti
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - F Tatangelo
- Pathology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - S Lastoria
- Nuclear Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - M Raddi
- Nuclear Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - D Bilancia
- Medical Oncology Unit, S. Carlo Hospital, Potenza, Italy
| | - V Granata
- Radiology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - S Setola
- Radiology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - A Petrillo
- Radiology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - C Vitagliano
- Experimental Pharmacology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - P Gargiulo
- Clinical Trial Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - L Arenare
- Clinical Trial Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - A Febbraro
- Hospital Sacro Cuore di Gesu, Fatebenefratelli, Benevento, Italy
| | - E Martinelli
- Medical Oncology, Precision Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy. https://twitter.com/grikamartinelli
| | - F Ciardiello
- Medical Oncology, Precision Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy
| | - P Delrio
- Colorectal Oncological Surgery, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - A Budillon
- Experimental Pharmacology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. https://twitter.com/AlfredoBudillon
| | - M C Piccirillo
- Clinical Trial Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - A Avallone
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
| |
Collapse
|
5
|
Petrillo A, Lorenzen S, van Laarhoven H. Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma. ESMO Open 2022; 7:100613. [PMID: 36356415 PMCID: PMC9646664 DOI: 10.1016/j.esmoop.2022.100613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 09/28/2022] [Indexed: 11/09/2022] Open
Affiliation(s)
- A. Petrillo
- Medical Oncology Unit, Ospedale del mare, Naples, Italy,Correspondence to: Dr A. Petrillo, Medical Oncology Unit, Ospedale del mare, via E. Russo, Naples, Italy
| | - S. Lorenzen
- Department of Hematology and Oncology, Technical University, Munich, Germany
| | - H.W.M. van Laarhoven
- Department of Medical Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam,University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
6
|
Granata V, Fusco R, Venanzio Setola S, Sassaroli C, De Franciscis S, Delrio P, Danti G, Grazzini G, Faggioni L, Gabelloni M, Ottaiano A, Greggi S, Patrone R, Palaia R, Petrillo A, Izzo F. Radiological assessment of peritoneal carcinomatosis: a primer for resident. Eur Rev Med Pharmacol Sci 2022; 26:2875-2890. [PMID: 35503632 DOI: 10.26355/eurrev_202204_28619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
The imaging has critical responsibility in the assessment of peritoneal lesions along with estimating the overall extent. Valuing disease burden is crucial for selection of combining cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) treatment. An approach that combines the strength of several imaging tools and increases diagnostic accuracy, should be chosen, even if the preferred imaging tool in patients with suspected Peritoneal Carcinomatosis (PC) is CT. The outcomes of PC are mainly correlated to tumor spread, localization, and lesion size. Accurate assessment of these features is critical for prognosis and treatment planning. These data can be evaluated by Peritoneal Cancer Index (PCI), a quantitative index suggested by Harman and Sugarbaker. Additionally, precise predictive biomarkers should be established to predict PC in patients at risk. The radiomics analysis could predict PC throughout the evaluation of cancers heterogeneity.
Collapse
Affiliation(s)
- V Granata
- Division of Radiology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Granata V, Fusco R, Venanzio Setola S, Barretta ML, Iasevoli DMA, Palaia R, Belli A, Patrone R, Tatangelo F, Grazzini G, Grassi R, Grassi F, Grassi R, Anselmo A, Izzo F, Petrillo A. Diagnostic performance of LI-RADS in adult patients with rare hepatic tumors. Eur Rev Med Pharmacol Sci 2022; 26:399-414. [PMID: 35113415 DOI: 10.26355/eurrev_202201_27864] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE The rare hepatic tumor can have a wide spectrum of radiologic features, representing a diagnostic challenge. Our purpose is to report the experience of a National Cancer Center, emphasizing the radiological features encountered and assessing the LR-M categories in the diagnostic performances for these lesions. PATIENTS AND METHODS We assessed 113 patients who underwent surgical resection or biopsy for rare liver lesions from May 2010 to December 2020. For these patients a computerized search of radiological records was performed to identify which had been studied with MRI and CT. For each lesion, the radiologists recorded the attenuation on CT studies and signal intensity (SI) in T1 weighted (W), in T2-W, DWI and in the related map of the apparent diffusion coefficient (ADC). We assessed the presence and the type of contrast enhancement (CE) during contrast study on CT and MRI and the enhancement was categorized according to LI-RADS 2018. We also assessed the presence of other features in LR-M categories (ancillary LR-M features) in order to classify different subgroups. The lesions were classified according to LR categories, and the gold standard was histological analysis. RESULTS The final study population included 95 patients (46 females and 49 males), with a mean age of 51 years (range 38-83 years). 83 patients had solid lesions, 12 patients had cystic lesions (simple or complex). According to histological analysis, we categorized 79 patients with malignant lesions and 16 patients with benign lesions. According to radiological features we assessed as malignant 82 patients (79 true malignant and 3 false malignant), as benign 13 patients (all true benign). Therefore, sensitivity, specificity, positive predictive value, negative predictive value and accuracy of radiological features to identify benign and malignant lesions were 100.0%, 81.3%, 96.3%, 100.0% and 96.8%, respectively. We found no significant difference in signal and contrast enhancement appearance among all LR-M categories (p-value =0.34 at Chi square test). However, among LR-M categories the presence of satellite nodules was a feature typical of cHCC-CC (p-value < 0.05 at Chi square test). The presence of intra lesion necrosis and haemorrhage was suggestive of sarcoma (p-value < 0.05 at Chi square test). CONCLUSIONS High diagnostic accuracy was obtained by LI-RADS classification between malignant and benign lesion. The presence of ancillary features could help the radiologist towards a correct diagnosis.
Collapse
Affiliation(s)
- V Granata
- Division of Radiology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Granata V, Grassi R, Fusco R, Izzo F, Brunese L, Delrio P, Avallone A, Pecori B, Petrillo A. Current status on response to treatment in locally advanced rectal cancer: what the radiologist should know. Eur Rev Med Pharmacol Sci 2021; 24:12050-12062. [PMID: 33336723 DOI: 10.26355/eurrev_202012_23994] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The assessment of tumor response, after neoadjuvant radiochemotherapy (nCRT), allows stratifying the patient in order to consider the proper therapeutical management. Histopathology analysis of the surgical specimen is considered the gold standard to assess tumour response and the definition of a complete cancer response is related to the clinical and endoscopic features, by direct evaluation of the rectal wall. However, imaging studies, especially Magnetic Resonance Imaging (MRI) have provided additional parameters, as the evaluation of nodal or mesorectal status. MRI provides a radiological tumour regression grade (mrTRG) that is correlated with the pathologic tumor regression grade (pTRG). Functional MRI parameters have additional impending in early prediction of the efficacy of therapy and can be valuable in drug development processes. Some of functional methodologies are already part of clinical practice: diffusion-weighted MRI (DW-MRI) and perfusion imaging (dynamic contrast enhanced MRI [DCE-MRI]). Other technologies, such as radiomics with MRI are still in the experimental phase. An adequate radiological report describing the restaging of rectal cancer after nCRT should be a "structured report" to improve communication in a multidisciplinary team.
Collapse
Affiliation(s)
- V Granata
- Division of Radiology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Trapani D, Lengyel CG, Habeeb BS, Altuna SC, Petrillo A, El Bairi K, Hussain S, Mazher SA, Elfaham EM, Curigliano G, Khan SZ. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. J Cancer Policy 2021; 28:100285. [PMID: 35559914 DOI: 10.1016/j.jcpo.2021.100285] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 04/01/2021] [Accepted: 04/20/2021] [Indexed: 02/08/2023]
Abstract
AIM OF THE STUDY Barriers in access to essential care are key determinants of disparities in cancer survival. Breast cancer (BC) is the most common cancer and lead cause of mortality among women, 60 % occurring in low- and middle-income countries (LMs). A quarter of BC are characterized by an over-expression of the epidermal growth factor receptor 2 (HER2). Valuable strategies to diagnose and manage patients with HER2-positive BC have been determined and some considered essential health interventions. ONCOLLEGE-001 is a global survey of availability, accessibility, and affordability of essential HER2 diagnostics and therapeutics. METHOD A self-administered questionnaire was shared electronically to oncologists, identified from oncology networks. Data were analyzed using descriptive statistics, per income areas and geographic regions. RESULTS We received 191 responses (84 % response rate). The majority of the responders were from LMs (n = 153) and were physician providers. Immunohistochemistry was the most common HER2 diagnostics available (n = 185). A third of the responders from low/lower-middle and a half of upper-middle income countries had HER2 testing only in the private sector. Trastuzumab was not available for 8 %: when available, 15%-21% reported accessibility only as out-of-pocket expenditure; when not reimbursed, only 10 % of the providers could significantly offer this intervention. Availability of trastuzumab biosimilars was reported in more than a half of the responders (n = 107). CONCLUSION Stark disparities are reported, with high out-of-pocket expenses for HER2 testing and significant financial barriers to access trastuzumab treatments. Policy solutions are urgently warranted for the selection, prioritization, and reimbursement of essential health interventions, to result in improved population health. POLICY SUMMARY STATEMENT: the inclusion of essential services for cancer management should be assured and financed in the benefit packages of healthcare to all. Prioritizing high-value health interventions, including medicines and medical devices, is critical to deliver impactful programs on population health.
Collapse
Affiliation(s)
- D Trapani
- European Institute of Oncology, IRCCS, Milan, Italy.
| | - C G Lengyel
- Head and Neck Surgery, National Institute of Oncology, Budapest, Hungary
| | - B S Habeeb
- Medical Oncology Department, Shaqlawa Teaching Hospital, Erbil, Iraq
| | - S C Altuna
- Department of Medical Oncology, Oncomedica C.A., Caracas, Venezuela
| | - A Petrillo
- Medical oncology unit, Ospedale del Mare, Naples, Italy
| | - K El Bairi
- Cancer Biomarkers Working Group, Oujda, Morocco
| | - S Hussain
- North West Cancer Center, Western Health and Social Care Trust, Altnagelvin Hospital, Londonderry BT47 6SB, UK
| | - S A Mazher
- UT Southwestern Clements University Hospital, Dallas, TX 75390, USA
| | - E M Elfaham
- Department of Clinical Oncology, Alexandria University Students Hospital, Alexandria, Egypt
| | - G Curigliano
- European Institute of Oncology, IRCCS, Milan, Italy; University of Milan, Department of Oncology and Hematology (DIPO), Milan, Italy
| | - S Z Khan
- Department of Clinical Oncology, Bannu Institute of Nuclear Medicine Oncology and Radiotherapy (BINOR), Bannu, KPK, Pakistan
| |
Collapse
|
10
|
Raiano N, Raiano C, Mazio F, Rossi I, Bordino U, De Simone G, Fusco R, Granata V, Cerciello V, Setola SV, Petrillo A. Home mobile radiography service in the COVID-19 era. Eur Rev Med Pharmacol Sci 2021; 25:3338-3341. [PMID: 33928621 DOI: 10.26355/eurrev_202104_25745] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Demographic changes in the Western world linked to the increase in the elderly population, life expectancy and above all cancer patients and chronically ill patients, often entrusted to home care or in healthcare residences, highlight an exponential increase in requests for diagnostic tests at home. Conventional radiographic examinations, such as thoracic, musculoskeletal and abdominal images are the most requested and are important first level diagnostic tests. To date and, in particular, in times of COVID-19 emergency, these patients need to be transferred to the hospital to perform radiological examinations which involve an increase in costs for the health system and an increased risk for the health of these patients, already often debilitated and immunocompromised. This article discussed the benefits of taking conventional chest x-rays directly at the patient's home.
Collapse
Affiliation(s)
- N Raiano
- Radiology Division, "Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale", Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Granata V, Fusco R, Amato DM, Albino V, Patrone R, Izzo F, Petrillo A. Beyond the vascular profile: conventional DWI, IVIM and kurtosis in the assessment of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2021; 24:7284-7293. [PMID: 32706066 DOI: 10.26355/eurrev_202007_21883] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVE To describe the role of the Diffusion Weighted Imaging (DWI) in the assessment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS Several electronic databases were evaluated in the present review. The search included articles published from January 2010 to May 2019. The references of all articles were also evaluated. All titles and abstracts were assessed, and only the studies of DWI in patients with HCC were retained. RESULTS HCC is the most common primitive hepatic cancer. The non-invasive radiological criteria for HCC diagnosis are based on the presence of the specific vascular profile characterized by contrast uptake during arterial phase, defined as arterial hyperenhancement, followed by washout in the venous/portal phase. However, arterial hyperenhancement and wash out appearance have a sensitivity rate of 50-60% in lesion smaller than 2 cm. Therefore, other functional parameters have been introduced in the detection and characterization of HCC nodules. DWI has been applied to liver imaging as an excellent tool for detection and characterization of focal liver lesions, increasing clinical confidence and decreasing false positives. The assessment of DW images can be done qualitatively and quantitatively, through the apparent diffusion coefficient (ADC) map. Intravoxel incoherent motion (IVIM) is a more sophisticated analysis, a biexponential model, to better defining the relationship between signal attenuation and increasing b value that separately reproduces tissue diffusivity and tissue perfusion. Traditionally DWI approach to analyze data is founded on the hypothesis that water molecules diffuse within a voxel following a single direction with a Gaussian behavior without any restriction. However, according to the presence of microstructures, water molecules within biologic tissues exhibits a non-Gaussian phenomena proposed by Jensen in 2005 called Diffusion Kurtosis Imaging (DKI). This approach assesses the kurtosis coefficient (K) that shows the deviance of diffusion from a Gaussian approach, and the diffusion coefficient (D) with the correction of non-Gaussian bias. DKI is an advanced DWI model that quantifies non-Gaussian behavior of diffusion and provides both a corrected ADC, as well as the excess kurtosis of tissue, a measure of the extent to which tissue diffusion deviates from a Gaussian pattern. It is believed that the DKI model is more sensitive to tissue microstructural complexity than standard DW. CONCLUSIONS DWI should be an integral part of study protocol for HCC patients, considering the great advantages due to DWI and DWI-based approaches in detection and characterization of HCC.
Collapse
Affiliation(s)
- V Granata
- Department of Radiology, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy.
| | | | | | | | | | | | | |
Collapse
|
12
|
Granata V, Palaia R, Albino V, Piccirillo M, Venanzio Setola S, Petrillo A, Izzo F. Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: a case report. Eur Rev Med Pharmacol Sci 2021; 24:7051-7057. [PMID: 32633399 DOI: 10.26355/eurrev_202006_21698] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Cholangiocarcinoma (CCA) is the second most common primary hepatic malignancy after hepatocellular carcinoma. The current standard palliative treatment, chemotherapy regimen with gemcitabine and cisplatin, prolongs overall survival only of a few months. Established locoregional therapies are not a curative option or an alternative to surgery in the treatment of CCA. We report a case of a patient affected by a cholangiocellular carcinoma at hepatic hilum treated by Electrochemotherapy (ECT) at our oncologic center. CASE PRESENTATION A 71 years old male affected by a CCA at hepatic hilum was treated with ECT according to ESOPE guidelines. No complications occurred during ECT procedure. The patient was discharged after 10 days. The functional MR evaluation at 2 and at 4 months post-treatment showed a significant response without significant post-treatment adverse events. The Computed tomography (CT) assessment after 18 months did not show progression of disease. CONCLUSIONS ECT is safe and its use could be suggested as a palliative treatment of advanced neoplastic lesions in which radical surgical treatment is not possible.
Collapse
Affiliation(s)
- V Granata
- Division of Radiology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy.
| | | | | | | | | | | | | |
Collapse
|
13
|
Granata V, Fusco R, Venanzio Setola S, Mattace Raso M, Avallone A, De Stefano A, Nasti G, Palaia R, Delrio P, Petrillo A, Izzo F. Liver radiologic findings of chemotherapy-induced toxicity in liver colorectal metastases patients. Eur Rev Med Pharmacol Sci 2020; 23:9697-9706. [PMID: 31799635 DOI: 10.26355/eurrev_201911_19531] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
There are a number of chemotherapy-effects that should be assessed with liver imaging since they have an influence on surgical morbidity. Chemotherapy-related complications, steatosis, chemotherapy-associated steatohepatitis (CASH), and SOS might impair the hepatic parenchyma, thus reducing the functionality and influencing the outcome following resection. The main role of a radiologist is to provide an accurate diagnosis of the lesion. With constant advances in medicine, a radiologist's role should extend beyond just reporting the data of tumor, providing additional information that may greatly improve patient care. Radiologists should assess both chemotherapy effects on the hepatic metastasis itself, as well as chemo-induced focal and diffuse modifications of non-tumor hepatic parenchyma, since it is important to avoid impaired hepatic function after hepatic resection.
Collapse
Affiliation(s)
- V Granata
- Division of Radiology, Division of Abdominal Oncology, Division of Hepatobiliary Surgical Oncology; "Istituto Nazionale Tumori - IRCCS, Fondazione G. Pascale", Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Altuna S, Trapani D, Lengyel C, Habeeb B, Hussain S, Mazher S, Elfaham E, Petrillo A, El Bairi K, Khan S. Accessibility and affordability to trastuzumab for breast cancer patients: Voices of the global oncology community from ONCOLLEGE 001 survey, part 2. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz263.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Altuna S, Lengyel C, Trapani D, Elfaham E, Hussain S, Petrillo A, El Bairi K, Mazher S, Habeeb B, Khan S. Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz095.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Budillon A, Delrio P, Pecori B, Tatangelo F, Di Gennaro E, Romano C, D'Angelo V, Marone P, Granata C, Cavalacanti E, De Stefano A, Pace U, Bianco F, Petrillo A, Lastoria S, Botti G, Muto P, Perrone F, Piccirillo M, Avallone A. Phase I/II study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.045] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Avallone A, Delrio P, Nasti G, Cassata A, Silvestro L, De Stefano A, Lastoria S, Casaretti R, Romano C, Ottaiano A, Di gennaro E, Nappi A, Maiolino P, Cavalcanti E, Petrillo A, Tatangelo F, Giannarelli D, Galon J, Ascierto P, Budillon A. Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Carotenuto A, Cutolo A, Petrillo A, Fusco R, Arra C, Sansone M, Larobina D, Cardoso L, Fraldi M. Growth and in vivo stresses traced through tumor mechanics enriched with predator-prey cells dynamics. J Mech Behav Biomed Mater 2018; 86:55-70. [DOI: 10.1016/j.jmbbm.2018.06.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 05/10/2018] [Accepted: 06/05/2018] [Indexed: 12/27/2022]
|
19
|
Petrillo A, Laterza M, Ventriglia J, Savastano B, Tirino G, Pompella L, Pappalardo A, Orditura M, Ciardello F, De Vita F. HER2 negative metastatic gastric cancer (mGC): a retrospective analysis on the efficacy of doublet or triplet chemotherapy (CT) as a first-line therapy in the clinical practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Laterza M, Ciaramella V, Morgillo F, Belli V, Petrillo A, Tirino G, Pompella L, Savastano B, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Ventriglia J, Laterza M, Savastano B, Petrillo A, Tirino G, Pompella L, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis on the efficacy and safety profile. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Bruixola G, Caballero J, Papaccio F, Petrillo A, Pastor M, Cervantes A. Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Ventriglia J, Laterza M, Savastano B, Petrillo A, Tirino G, Pompella L, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Safety and efficacy of gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.139] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Laterza M, Ciaramella V, Morgillo F, Belli V, Tirino G, Pompella L, Petrillo A, Savastano B, Pappalardo A, Orditura M, Ciardiello F, De Vita F. Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Ventriglia J, Petrillo A, Huerta M, Laterza M, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Febbraro A, Troiani T, Orditura M, Cervantes A, Ciardiello F, De Vita F. Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Petrillo A, Laterza M, Ventriglia J, Savastano B, Tirino G, Pompella L, Martinelli E, Morgillo F, Orditura M, Ciardiello F, De Vita F. Prognostic implications of baseline neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in metastatic gastric cancer (GC) patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.44] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Leongito M, Palaia R, Albino V, Di Giacomo R, Amore A, Piccirillo M, Tafuto S, Granata V, Petrillo A, Lastoria S, Izzo F. Electrochemotherapy with bleomycin in locally advanced pancreatic adenocarcinoma. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.04.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
28
|
Ventriglia J, laterza M, Capasso A, Belli V, Savastano B, Petrillo A, Tirino G, Pompella L, Diana A, Orditura M, Ciardiello F, De Vita F. GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Savastano B, laterza M, Capasso A, Belli V, Ventriglia J, Petrillo A, Tirino G, Pompella L, Morgillo F, Martinelli E, Orditura M, Ciardiello F, De Vita F. The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab resistant gastric cancer cell lines. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
De Vita F, Niger M, Vivaldi C, Giommoni E, Zaniboni A, Bozzarelli S, Tomasello G, Sava T, Spada M, Menatti E, Proserpio I, Galdy S, Bittoni A, Bencardino K, Squadroni M, Latiano T, Spallanzani A, Tirino G, Petrillo A, Di Bartolomeo M. Ramucirumab as second line therapy in metastatic gastric cancer (MGC): results of the Italian compassionate-use named patients. The RAMoss study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Petrillo A, Laterza M, Ventriglia J, Savastano B, Tirino G, Pompella L, Diana A, Martinelli E, Morgillo F, Orditura M, Ciardello F, De Vita F. A prognostic model using inflammatory response markers in metastatic gastric cancer (GC) pts before first-line chemotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
32
|
Corvino A, Catalano O, Corvino F, Sandomenico F, Setola SV, Petrillo A. Superficial temporal artery pseudoaneurysm: what is the role of ultrasound? J Ultrasound 2016; 19:197-201. [PMID: 27635165 DOI: 10.1007/s40477-016-0211-8] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2016] [Accepted: 05/11/2016] [Indexed: 12/22/2022] Open
Abstract
PURPOSE The superficial temporal artery (STA) is one of the terminal branches of the external carotid artery; STA pseudoaneurysms are uncommon vascular lesion, generally subsequent to blunt or penetrating trauma that could represent a trick for radiologist, especially when the only anamnestic information is "palpable superficial swelling". In this article, we describe our ultrasonographic experience about STA pseudoaneurysm reporting several cases with different etiopatogenesis. METHODS Between January 2004 and March 2015 six patients (4F and 2M; aged 15-55 years, mean 36 year) presented at our department with superficial palpable swelling in temporal region (four with trauma history, two with iatrogenic cause) underwent to ultrasonographic study to assess the presence of STA pseudoaneurysm. Ultrasonographic findings suggestive of pseudoaneurysm was a well-defined, pulsatile, anechoic mass in B-mode, a swirling or disorganized pattern of blood flow in the lesion with demonstration of direct communication between arterial lumen and pseudoaneurysm at colour-Doppler and a typical to-and-fro waveform on pseudoaneurysm neck at pulsed-Doppler. RESULTS B-mode proves the presence of anechoic mass in five on six patients. Colour-Doppler demonstrates the presence of flow inside the lesion in five patients and a direct communication in all patients. To-and-fro typical waveform has been demonstrated in five patients. Ultrasound made diagnosis in all patients with a sensibility and specificity of 100 %. CONCLUSION US is the imaging modality of choice, since it can provide detailed information about vascular anatomy without incurring the risks of invasive methods like angiography or radiation.
Collapse
Affiliation(s)
- A Corvino
- Department of Advanced Medical Biosciences, University Federico II of Naples (UNINA), Biostructures and Bioimmages Institution (IBB), National Research Council (CNR), via Pansini 5, 80131 Naples, Italy
| | - O Catalano
- Department of Radiology, National Cancer Institute, Pascale Foundation, via M. Semmola, 80131 Naples, Italy
| | - F Corvino
- Department of Advanced Medical Biosciences, University Federico II of Naples (UNINA), Biostructures and Bioimmages Institution (IBB), National Research Council (CNR), via Pansini 5, 80131 Naples, Italy
| | - F Sandomenico
- Department of Radiology, National Cancer Institute, Pascale Foundation, via M. Semmola, 80131 Naples, Italy
| | - S V Setola
- Department of Radiology, National Cancer Institute, Pascale Foundation, via M. Semmola, 80131 Naples, Italy
| | - A Petrillo
- Department of Radiology, National Cancer Institute, Pascale Foundation, via M. Semmola, 80131 Naples, Italy
| |
Collapse
|
33
|
Grimaldi A, Ascierto P, Simeone E, Giannarelli D, Falivene S, Borzillo V, Giugliano F, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caraco C, Ciliberto G, Mozzillo N, Muto P. EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32642-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Savastano B, Ventriglia J, Laterza M, Petrillo A, Tirino G, Diana A, Fabozzi A, Giordano G, Orditura M, Ciardiello F, De Vita F. Prognostic value of blood neutrophil-to-lymphocyte ratio (NLR)in advanced pancreatic cancer patients treated with Nab-paclitaxel and Gemcitabine: our experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Laterza M, Petrillo A, Ventriglia J, Fabozzi A, Savastano B, Diana A, Martinelli E, Morgillo F, Ciardiello F, De Vita F. Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Ventriglia J, Laterza M, Savastano B, Petrillo A, Tirino G, Diana A, Troiani T, Ciardiello F, De Vita F. Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Laterza M, Petrillo A, Ventriglia J, Fabozzi A, Savastano B, Tirino G, Orditura M, Diana A, Ciardiello F, De Vita F. 2392 Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31308-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Laterza M, Petrillo A, Ventriglia J, Savastano B, Diana A, Tirino G, Martinelli E, Orditura M, Ciardiello F, de Vita F. P-062 Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Corvino A, Catalano O, Setola SV, Sandomenico F, Corvino F, Petrillo A. Contrast-enhanced ultrasound in the characterization of complex cystic focal liver lesions. Ultrasound Med Biol 2015; 41:1301-1310. [PMID: 25666723 DOI: 10.1016/j.ultrasmedbio.2014.12.667] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Revised: 11/13/2014] [Accepted: 12/29/2014] [Indexed: 06/04/2023]
Abstract
Complex cystic focal liver lesions (FLLs) found at non-contrast ultrasound (US) may turn out to be malignant. In this prospective, monocentric study we investigated the value of contrast-enhanced US (CEUS) in the differential diagnosis of complex cystic FLLs. In the past 3 years, all patients with complex cystic FLLs unclassifiable at US underwent CEUS with low-transmit insonation power. We evaluated 36 consecutive patients with 61 FLLs (1-6/patient, mean = 2). The diameter of the lesions ranged from 1.1 to 7.9 cm (mean = 3.9 cm). Sixteen patients had an extrahepatic malignancy. There were 42 malignant lesions and 19 benign lesions. No lesion had a certain diagnosis at conventional US, whereas 16 FLLs were classified as probable (benign or malignant) and 45 as uncertain. CEUS correctly categorized 95% of the malignant cases. CEUS was not able to differentiate the biliary cystadenoma from its malignant counterpart and misdiagnosed two abscesses. Complete non-enhancement throughout three phases or sustained enhancement in the portal/late phase was exhibited in most benign complex cystic FLLs, except for 1 (of the 3) cystadenomas and in 2 (of the 4) abscesses. On the other hand, all malignant lesions presented a contrast washout with a hypo-enhancing appearance. CEUS may provide added diagnostic value in all complex cystic FLLs found uncertain at conventional US, potentially avoiding the use of more invasive and expensive imaging modalities.
Collapse
Affiliation(s)
- A Corvino
- Department of Radiology and Institute of Biostructures, University Federico II, Naples, Italy; First Department of Radiology, National Cancer Institute, Fondazione Pascale, Naples, Italy.
| | - O Catalano
- First Department of Radiology, National Cancer Institute, Fondazione Pascale, Naples, Italy
| | - S V Setola
- First Department of Radiology, National Cancer Institute, Fondazione Pascale, Naples, Italy
| | - F Sandomenico
- First Department of Radiology, National Cancer Institute, Fondazione Pascale, Naples, Italy
| | - F Corvino
- Department of Radiology and Institute of Biostructures, University Federico II, Naples, Italy
| | - A Petrillo
- First Department of Radiology, National Cancer Institute, Fondazione Pascale, Naples, Italy
| |
Collapse
|
40
|
Izzo F, Palaia R, Albino V, Di Giacomo R, Amore A, Saponara R, Leongito M, Setola S, Granata V, Petrillo A. 28. Electrochemotherapy in advanced pancreatic adenocarcinoma. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
41
|
Laterza M, Orditura M, Fabozzi A, Ventriglia J, Savastano B, Petrillo A, Giordano G, Martinelli E, Gambardella V, Ciardiello F, De Vita F. Increased Vegf-C Serum Levels are Predictive of a Poor Outcome in Patients with Resectable Gastric Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Granata V, Fusco R, Piccirillo M, Palaia R, Lastoria S, Petrillo A, Izzo F. Feasibility and Safety of Intraoperative Electrochemotherapy in Locally Advanced Pancreatic Tumor: A Preliminary Experience. EUR J INFLAMM 2014. [DOI: 10.1177/1721727x1401200308] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Electrochemotherapy is an effective treatment for various cutaneous tumors and could be translated into treatment of deep-seated tumors. With this aim, a prospective clinical phase I/II study was conducted to evaluate the feasibility and safety of intraoperative Electrochemotherapy (ECT) in locally advanced pancreatic adenocarcinoma: the preliminary results are reported in this study. The secondary endpoint was to assess treatment response in terms of morphological and functional criteria based on Magnetic Resonance Imaging. Eleven consecutive patients were enrolled in a clinical phase I/II study approved by the Ethics Committee of the National Cancer Institute G. Pascale Foundation - IRCCS of Naples. Electrochemotherapy with bleomycin was performed during open surgery. All patients underwent MR and CT scan, before and after ECT treatment, using morphological and functional imaging. RECIST criteria were used to evaluate ECT response on CT and MR images. Functional parameters were also used to evaluate ECT response on MR images. No acute (intraoperative) and/or postoperative serious adverse events related to electrochemotherapy were observed; no clinically significant electrocardiographic, hemodynamic, or serum biologic changes were noted. No clinically relevant elevation of amylase or lipase levels was observed and no bleeding or damage to surrounding viscera occurred. Electrochemotherapy of locally advanced pancreatic adenocarcinoma proved to be a feasible and safe treatment modality. Dynamic and diffusion MR imaging is more suitable to assess ECT treatment response than CT imaging and morphological MR alone, after one month of treatment.
Collapse
Affiliation(s)
- V. Granata
- Diagnostic Imaging Department, “Istituto Nazionale Per Lo Studio e La Cura Dei Tumori Fondazione Giovanni Pascale - IRCCS”, Naples, Italy
| | - R. Fusco
- Diagnostic Imaging Department, “Istituto Nazionale Per Lo Studio e La Cura Dei Tumori Fondazione Giovanni Pascale - IRCCS”, Naples, Italy
| | - M. Piccirillo
- Hepato-biliary Surgery Department, “Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale - IRCCS”, Naples, Italy
| | - R. Palaia
- Hepato-biliary Surgery Department, “Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale - IRCCS”, Naples, Italy
| | - S. Lastoria
- Diagnostic Imaging Department, “Istituto Nazionale Per Lo Studio e La Cura Dei Tumori Fondazione Giovanni Pascale - IRCCS”, Naples, Italy
| | - A. Petrillo
- Diagnostic Imaging Department, “Istituto Nazionale Per Lo Studio e La Cura Dei Tumori Fondazione Giovanni Pascale - IRCCS”, Naples, Italy
| | - F. Izzo
- Hepato-biliary Surgery Department, “Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale - IRCCS”, Naples, Italy
| |
Collapse
|
43
|
Laterza M, Orditura M, Fabozzi A, Ventriglia J, Savastano B, Petrillo A, Giordano G, Martinelli E, Gambardella V, Ciardiello F, De Vita F. Increased Vegf-C Serum Levels are Predictive of a Poor Outcome in Patients with Resectable Gastric Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Morgillo F, De Vita F, Antoniol G, Orditura M, Auriemma PP, Diadema MR, Lieto E, Savastano B, Festino L, Laterza MM, Fabozzi A, Ventriglia J, Petrillo A, Ciardiello F, Barbarisi A, Iovino F. Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer. ACTA ACUST UNITED AC 2013; 20:e283-8. [PMID: 23904766 DOI: 10.3747/co.20.1380] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Increased insulin-like growth factor (igf) signalling has been observed in breast cancer, including endocrine-responsive cancers, and has been linked to disease progression and recurrence. In particular, igf-1 has the ability to induce and promote lymphangiogenesis through the induction of vascular endothelial growth factor C (vegfc). In the present study, we analyzed serum and tumour samples from 60 patients with endocrine-positive breast cancer to determine the expression and the possible relationship of circulating igf-1, igf binding protein 3 (igfbp3), and vegfc with the presence of lymphatic metastasis and other immunohistochemical parameters. The analysis revealed a clear and significant correlation between high basal levels of igf-1, igfbp3, and vegfc and lymph node metastasis in endocrine-responsive breast cancer. In addition, expression of those molecules was significantly higher in breast cancer patients than in healthy control subjects. Those findings may enable more accurate prediction of prognosis in patients with breast cancer.
Collapse
Affiliation(s)
- F Morgillo
- Oncologia Medica, Dipartimento di Internistica Clinica e Sperimentale "F.Magrassi e A. Lanzara", Seconda Università degli Studi di Napoli, Napoli, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Marone U, Catalano O, Caracò C, Anniciello AM, Sandomenico F, Di Monta G, Di Cecilia ML, Mori S, Botti G, Petrillo A, Mozzillo N. Can high-resolution ultrasound avoid the sentinel lymph-node biopsy procedure in the staging process of patients with stage I-II cutaneous melanoma? Ultraschall Med 2012; 33:E179-E185. [PMID: 22923259 DOI: 10.1055/s-0032-1312827] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
PURPOSE The objective of our study was to define the diagnostic accuracy of high-resolution ultrasound (US) in detecting nodal involvement before sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma, to define the sonographic criteria used to assess nodal metastases, and to establish if high-resolution US can directly select patients to radical lymphadenectomy, sparing selective lymphadenectomy. MATERIALS AND METHODS 623 patients underwent high-resolution US of the regional lymph nodes, 24 hours prior being submitted to the sentinel lymph node biopsy procedure. The US findings were compared with histological findings. RESULTS In 14.7 % out of 122 excised lymph nodes, high-resolution US showed sonographic features consistent with malignant involvement before the surgical step. US scan sensitivity and specificity were 15 and 100 %, respectively, since positive and negative predictive values were 100 and 87 % respectively. CONCLUSION US is an effective modality in the presurgical detection of subclinical deposits within sentinel lymph nodes. However, preoperative staging work-up with high-resolution US cannot substitute the SLNB, mainly because of low sensitivity due to missing many micrometastases.
Collapse
Affiliation(s)
- U Marone
- Melanoma - Soft Tissues - Head & Neck - Skin Cancers, INT Pascale
| | | | - C Caracò
- Melanoma - Soft Tissues - Head & Neck - Skin Cancers, INT Pascale
| | | | | | - G Di Monta
- Melanoma - Soft Tissues - Head & Neck - Skin Cancers, INT Pascale
| | - M L Di Cecilia
- Melanoma - Soft Tissues - Head & Neck - Skin Cancers, INT Pascale
| | - S Mori
- Melanoma - Soft Tissues - Head & Neck - Skin Cancers, INT Pascale
| | - G Botti
- Department of Pathology, INT Pascale
| | | | - N Mozzillo
- Melanoma - Soft Tissues - Head & Neck - Skin Cancers, INT Pascale
| |
Collapse
|
46
|
Avallone A, Di Gennaro E, Aloj L, Delrio P, Pecori B, Tatangelo F, Petrillo A, Iaffaioli V, Lastoria S, Budillon A. Neoadjuvant Multidisciplinary Phase II Study (BRANCH) of an Early Bevacizumab Schedule Plus Chemo-Radiation Therapy in Rectal Cancer: Efficacy, Safety, and Biomarkers. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33177-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
|
48
|
Cardone E, Delrio P, Avallone A, Pecori B, Budillon A, De Gennaro E, Lastoria S, Tatangelo F, Marone P, Petrillo A, Romano C, Sassaroli C, Bianco F, Cremona F, Romano G. Circulating endothelial cells and FDG-PET as markers for early prediction of response to neoadjuvant chemoradiation and bevacizumab for locally advanced rectal cancer. Eur J Surg Oncol 2010. [DOI: 10.1016/j.ejso.2010.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
49
|
Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Cozzolino D, Del Genio G, Santoriello C. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2010; 50:317-23. [DOI: 10.1093/rheumatology/keq176] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
50
|
Frasci G, D’Aiuto G, Comella P, D’Aiuto M, Di Bonito M, Ruffolo P, Iodice G, Petrillo A, Lastoria S, Oliviero P, Capasso I, Montella M, Siani C, Santangelo M, Vizioli L, Comella G. Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol 2010; 21:707-716. [DOI: 10.1093/annonc/mdp356] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
|